Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571789 | 0.82 | SLC18A3 (0.41) | NISCHALDH1A1HSD17B10KDM4EMAPT | |
| SCHEMBL240623 | 0.79 | ADCY5 (0.38) | NISCHMAPT | |
| SCHEMBL9375602 | 0.79 | CYP19A1 (0.33) | DDB1CRBNCHRNB2CHRNA4 | |
| SCHEMBL595524 | 0.79 | HTR3A (0.50) | — | |
| SCHEMBL10520604 | 0.79 | TAAR1 (0.39) | CYP1A2MAPT | |
| SCHEMBL1616732 | 0.79 | KDM1A (0.38) | — | |
| SCHEMBL9363501 | 0.79 | HTR2C (0.49) | NISCH | |
| SCHEMBL1461219 | 0.79 | CHRNB2 (0.50) | CYP1A2CYP2C19CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9331689 | 0.79 | MAOA (0.50) | NISCHALDH1A1KDM4E | |
| SCHEMBL10517231 | 0.75 | NISCH (0.39) | NISCHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | claimed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2012040444-A2 | TREATMENT OF PATIENTS WITH INCIPIENT ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | claimed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | claimed |
| EP-1465861-B1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | claimed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | claimed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | claimed |
| EP-1465861-A4 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1465861-A1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | claimed |
| WO-2003053912-A1 | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| WO-1999032466-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 1999-07-01 | — | — | WO | claimed |
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | RECQL 2300/4885NISCH 614/4885ADRB2 559/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | RECQL 2672/4885NISCH 2504/4885ADRB2 469/4885 |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | APBA1, APP, BACE1 | RECQL 2347/4885NISCH 2653/4885ADRB2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.